Streetbeat News

Earnings

REPL

Replimune Group reported Q1 losses of $(0.75) per share, beating the analyst consensus estimate of $(0.85) by 11.76%. This is a 3.85% increase over losses from the same period last year.

Portfolio Pulse from Happy Mohamed

August 04, 2023 | 1:14 pm

MYE

Myers Industries has projected its FY23 earnings per share (EPS) to be between $1.55 and $1.85, which is a range that includes the current estimate of $1.66.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:13 pm

APG

APi Group has increased its FY23 net revenues forecast from $6.875B-$7.025B to $7.015B-$7.075B, surpassing the consensus estimate of $6.98B.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:13 pm

KOP

Koppers Holdings has reaffirmed its 2023 sales forecast of $2.1 billion, which is slightly below the consensus estimate of $2.11 billion. The company also expects its adjusted EPS to be $4.40, slightly above the consensus estimate of $4.39.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:13 pm

WMS

Advanced Drainage Systems has confirmed its financial targets for FY24, with net sales expected to be between $2.60 billion and $2.80 billion. The estimated net sales are $2.74 billion.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:12 pm

LQDT

Liquidity Services has projected its Q4 adjusted EPS to be between $0.19 and $0.27, compared to the estimated $0.24.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:12 pm

PRLD

Prelude Therapeutics reported Q2 losses of $(0.54) per share, beating the analyst consensus estimate of $(0.63) by 14.29%. This is a 6.9% increase over losses from the same period last year. The company's cash, cash equivalents, and marketable securities of $255M are sufficient to fund operations into 2026.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:12 pm

MRMD

MariMed Inc. reported Q2 FY23 revenue of $36.5 million, a 10.7% YoY increase. However, adjusted EBITDA decreased by 29.4% to $6.3 million. The company also reported a net loss of $935,000 compared to income of $1.9 million in Q2 2022. MariMed's CEO highlighted the company's 14th consecutive quarter of positive adjusted EBITDA and strong balance sheet. The company expects 2023 revenue of at least $150 million and adjusted EBITDA of $32 million to $35 million.

Portfolio Pulse from Vuk Zdinjak

August 04, 2023 | 1:12 pm

TARA

Protara Therapeutics reported Q2 losses of $1.00 per share, missing the analyst consensus estimate of $0.87 by 14.94%. This represents a 25% increase in losses compared to the same period last year.

Portfolio Pulse from Happy Mohamed

August 04, 2023 | 1:12 pm

FOCS

Focus Financial Partners (NASDAQ:FOCS) reported Q2 earnings of $0.90 per share, missing the analyst consensus estimate of $0.97 by 7.22%. The company's quarterly sales were $583.80 million, missing the estimate of $593.55 million by 1.64%. This represents a 23.73% decrease in earnings and an 8.27% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:12 pm